Funded Project Details - FY2021
|Title:|| Profiling Alzheimer's Biomarkers|
|Congressional District Code:
||Biomedical Laboratory R&D
|| October 2017 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Abstract With our unique multi-component clinical sample and advances in Mass Spectrometry (MS), we hope to identify a combination of multiple biomarkers that provide discriminatory and accurate biomarkers of Alzheimer’s disease (AD) to advance earlier detection and treatment. Currently, the ratio of tau/Aβ in cerebrospinal fluid (CSF) is the best available biomarker for separating AD from normal subjects and predicting disease progression, but its sensitivity and specificity are modest. Our co...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.